When: April 3, 2019
Time: 12:00 – 1:00 p.m. ET
The global clinical trial market is expected to reach $68.9 billion by 2026. Factors such as globalization of clinical trials, innovations in treatments such as personalized medicine, and technological evolution are driving the growth. While developed economies are not poised to handle this growth—due to low patient recruitment, escalating trial budgets, and declining R&D productivity—emerging markets such as India can help address these challenges.
In the next Ad Hoc Lectures on Emerging Regulatory Trends (ALERT) Program series event, join John Sanil Manavalan, MD, Chief Medical Officer at Star Health Network, Inc. for a webinar as he discusses:
- The benefits of conducting trails in India, including the country’s access to a large number of patients and shorter trial timelines
- How outsourcing administrative aspects of research—as well as the regulatory and ethics filings—to India can substantially reduce time and economical expenses
- The regulatory hurdles and cultural and societal challenges to conducting trials in India, and how to overcome them
To register for the webinar, please indicate interest here for a unique webinar access link: https://bit.ly/2HdSAHx.
Please email Tom Koperniak, Assistant Teaching Professor of Regulatory Affairs, at email@example.com with any questions.
Dr. Manavalan is the co-founder and Chief Medical Officer of Star Health Network, Inc. and Chief Scientific Officer of Star Biosciences, Pvt Ltd. He has over 25 years of experience as an MD and a biomedical scientist. Previously, Sanil served as an Assistant Professor of Pathology and Medicine at Columbia University, Vagelos College of Physicians and Surgeons and served more than 10 years on Columbia University’s Institutional Review Board (IRB). He has over 40 publications in peer-reviewed medical journals, served on the Executive Editorial Board of the Human Immunology Journal, and as an Associate Director of a clinical laboratory at Columbia University.